Background: The real-world effectiveness of anti-VEGF treatment for MO secondary to RVO is well established. However, there is value in exploring the outcomes of a specific clinic to investigate whether the treatment regime is effective and consistent with research.
The aim of this retrospective observational study was to investigate the visual and anatomical response and treatment intensity of treatment naïve eyes with MO secondary to RVO.

Methods: Retrospective data of patients who attended a tertiary ophthalmic practice were included. De-identified patient data was extracted from the RVO module of the Fight Retinal Blindness! Registry from 24/2/2015 to 18/1/2021 and follow up was 24 months.

Results: 72 eyes from 69 patients with mean age of 65.8 years were included. 756 injections were recorded. 79.2% received at least 3 injections as a loading dose within the first 3 months and a median of 5 injections in the first 6 months. 29 eyes (40.3%) switched treatment and the first switch occurred a median of 7.6 months after initiation.
BCVA improved over the study period (p<0.05) with almost half improving by at least 5 letters at 6 months while over half had improved at least five letters at 12 and 24 months. CST also decreased significantly.

Conclusion: Treatment intensity was on the higher end compared with some real-world studies, as was the resultant BCVA. It is therefore worth considering treatment intensity as a factor in these patients and further research is needed to establish the impact of this in real-world clinics.